Showing 8351-8360 of 8647 results for "".
- OCT Screening Before Cataract Surgery Can Improve Outcomeshttps://modernod.com/news/oct-screening-before-cataract-surgery-can-improve-outcomes/2479699/The routine use of optical coherence tomography (OCT) to screen candidates for cataract surgery can improve surgery timing and planning, give patients realistic expectations, and even lead to changes in treatment plans, results from a new study show, according to a Medscape
- Prevent Blindness Elects Three New Members to National Board of Directorshttps://modernod.com/news/prevent-blindness-elects-three-new-members-to-national-board-of-directors-2/2479700/Prevent Blindness has announced that Paul Delatore, Global Head, Market Access at Alcon; Jim McGrann, Chairman & CEO of Healthy Eyes Advantage; and Rajeev S. Ramchandran, MD, Associate Professor of Ophthalmology in the University of Rochester Medical School’s Department of Ophthalmology, have
- Clearside Biomedical’s Combination Therapy in RVO Does Not Meet Primary Endpoint in Phase 3 Trialhttps://modernod.com/news/clearside-biomedicals-combination-therapy-in-rvo-does-not-meet-its-primary-endpoint-in-phase-3-trial/2479701/Clearside Biomedical announced that the primary endpoint was not achieved in its phase 3 clinical trial (SAPPHIRE) investigating the superiority of XIPERE (formerly suprachoroidal CLS-TA) used together with the intravitreal anti-VEGF agent Eylea (aflibercept), compared to intravit
- Unum Finds Significant Number of Millennials Value Vision Insurancehttps://modernod.com/news/unum-finds-significant-number-of-millennials-value-vision-insurance/2479704/Employee benefits provider Unum finds the elimination of vision benefits could motivate more than a third (34 percent) of U.S. workers ages 25 to 34 to look for a new job. These results and other key findings were part of an online poll among 1,227 working U.S. adults conducted by Unum in July.</
- SemaThera Board Names Garth Cumberlidge as President & CEOhttps://modernod.com/news/semathera-board-names-garth-cumberlidge-as-president-ceo/2479705/SemaThera announced that its board of directors has appointed Garth Cumberlidge as President and Chief Executive Officer. Dr. Cumberlidge was also elected to the board of directors of SemaThera. He will lead the company’s development programs in diabetic macular edema and other degenerative retin
- Medicare Plans to Phase in Changes for Office-Visit Paymentshttps://modernod.com/news/medicare-plans-to-phase-in-changes-for-office-visit-payments/2479706/The Centers for Medicare & Medicaid Services (CMS) said it will phase in changes to payments to physicians for office visits, proceeding over the objection of many medical groups with its overhaul of reimbursement for evaluation and management (E&M) services, according to a Medscape
- Oxurion Supporting Prevent Blindness Sight-Saving Programs for Those with Diabeteshttps://modernod.com/news/oxurion-supporting-prevent-blindness-sight-saving-programs-for-those-with-diabetes/2479709/To help support the fight against vision loss and blindness due to diabetes, Oxurion has partnered with Prevent Blindness. During the Diabetic Eye Disease Awareness Month in November, Oxurion will help Prevent Blindness promote awareness and education of the damaging effects that diabetes may hav
- Ophthalmologists Implant First Visian Toric ICLs in the UShttps://modernod.com/news/ophthalmologists-implant-first-visian-toric-icls-in-the-us/2479710/Staar Surgical announced the first patient implants of the company’s Visian Toric Implantable Collamer Lenses (TICLs) in the United States by Brinton Vision in St. Louis and Parkhurst NuVision in San Antonio. A select group of lea
- Nicox Postpones Nasdaq Listing Due to Market Volatilityhttps://modernod.com/news/nicox-postpones-nasdaq-listing-due-to-market-volatility/2479717/Nicox SA announced that due to the extreme volatility of the financial markets, it has decided to postpone its dual listing on Nasdaq, concluding that it would not be in the interest of their existing shareholders at this time, according to a company news release. The purpose of a Nasdaq l
- ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticalshttps://modernod.com/news/proqr-in-licenses-worldwide-rights-to-ophthalmology-drug-candidate-from-ionis-pharmaceuticals/2479723/ProQR Therapeutics announced the signing of an agreement with Ionis Pharmaceuticals to license QR-1123 (formerly IONIS-RHO-2.5Rx), an RNA medicine for autosomal dominant retinitis pigmentosa (adRP) caused by the P23H mutation in the rhodopsin (RHO) gene. “Building on th